MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206593 | Name: PNU-145156E (FCE26644)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PNU-145156E, also known as FCE26644, is a novel angiogenesis inhibitor. PNU-145156E blocked circulating angiogenesis-promoting growth factors in animal studies and exhibited an antitumor effect in murine solid tumors. PNU-145156E is chemically a polyanionic, polysulfonated derivative of distamycin A consisting in a skeleton of 4-methyl pyrrole rings ending in two naphthalene rings with four sulfonic groups in the 1,3 positions. PNU-145156E shows structural similarities to suramin. This compound is able to form complexes with different growth factors involved in the neoangiogenic process, in particular bFGF. Through this mechanism PNU-145156E inhibits the binding of bFGF to its receptor.

Chemical Structure

PNU-145156E (FCE26644)
PNU-145156E (FCE26644)
CAS#154788-16-6

Theoretical Analysis

MedKoo Cat#: 206593

Name: PNU-145156E (FCE26644)

CAS#: 154788-16-6

Chemical Formula: C45H36N10Na4O17S4

Exact Mass: 1208.0734

Molecular Weight: 1209.04

Elemental Analysis: C, 44.70; H, 3.00; N, 11.59; Na, 7.61; O, 22.50; S, 10.61

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PNU-145156E; PNU145156E; PNU 145156E; FCE26644; FCE-26644; FCE 26644.
IUPAC/Chemical Name
sodium 7,7'-((4,4'-((4,4'-(carbonylbis(azanediyl))bis(1-methyl-1H-pyrrole-4,2-diyl-2-carbonyl))bis(azanediyl))bis(1-methyl-1H-pyrrole-4,2-diyl-2-carbonyl))bis(azanediyl))bis(naphthalene-1,3-disulfonate)
InChi Key
XUWLTCQVQARIFB-UHFFFAOYSA-J
InChi Code
InChI=1S/C45H40N10O17S4.4Na/c1-52-19-27(13-35(52)41(56)46-25-7-5-23-9-31(73(61,62)63)17-39(33(23)11-25)75(67,68)69)48-43(58)37-15-29(21-54(37)3)50-45(60)51-30-16-38(55(4)22-30)44(59)49-28-14-36(53(2)20-28)42(57)47-26-8-6-24-10-32(74(64,65)66)18-40(34(24)12-26)76(70,71)72;;;;/h5-22H,1-4H3,(H,46,56)(H,47,57)(H,48,58)(H,49,59)(H2,50,51,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72);;;;/q;4*+1/p-4
SMILES Code
O=C(NC1=CN(C)C(C(NC2=CN(C)C(C(NC3=CC4=C(S(=O)([O-])=O)C=C(S(=O)([O-])=O)C=C4C=C3)=O)=C2)=O)=C1)NC5=CN(C)C(C(NC6=CN(C)C(C(NC7=CC8=C(S(=O)([O-])=O)C=C(S(=O)([O-])=O)C=C8C=C7)=O)=C6)=O)=C5.[Na+].[Na+].[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,209.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zamai M, Hariharan C, Pines D, Safran M, Yayon A, Caiolfa VR, Cohen-Luria R, Pines E, Parola AH. Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-c arbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding. Biophys J. 2002 May;82(5):2652-64. PubMed PMID: 11964252; PubMed Central PMCID: PMC1302054. 2: Groen HJ, de Vries EG, Wynendaele W, van der Graaf WT, Fokkema E, Lechuga MJ, Poggesi I, Dirix LY, van Oosterom AT. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. Clin Cancer Res. 2001 Dec;7(12):3928-33. PubMed PMID: 11751484. 3: Possati L, Campioni D, Sola F, Leone L, Ferrante L, Trabanelli C, Ciomei M, Montesi M, Rocchetti R, Talevi S, Bompadre S, Caputo A, Barbanti-Brodano G, Corallini A. Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model. Clin Exp Metastasis. 1999;17(7):575-82. PubMed PMID: 10845556. 4: Dhar S, Gullbo J, Csoka K, Eriksson E, Nilsson K, Nickel P, Larsson R, Nygren P. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000 Apr;36(6):803-9. PubMed PMID: 10762755. 5: Sola F, Capolongo L, Moneta D, Ubezio P, Grandi M. The antitumor efficacy of cytotoxic drugs is potentiated by treatment with PNU 145156E, a growth-factor-complexing molecule. Cancer Chemother Pharmacol. 1999;43(3):241-6. PubMed PMID: 9923555. 6: de Cupis A, Pirani P, Fazzuoli L, Favoni RE. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line: comparison between early and late cultures. In Vitro Cell Dev Biol Anim. 1998 Nov-Dec;34(10):836-43. PubMed PMID: 9870534. 7: Corallini A, Betti M, Rusnati M, Campioni D, Ciomei M, Sola F, Calza N, Zauli G, Presta M, Barbanti-Brodano G, Caputo A. Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein. AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1561-71. PubMed PMID: 9840289. 8: Zamai M, Caiolfa VR, Pines D, Pines E, Parola AH. Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate). Biophys J. 1998 Aug;75(2):672-82. PubMed PMID: 9675169; PubMed Central PMCID: PMC1299742. 9: de Cupis A, Ciomei M, Pirani P, Ferrera A, Ardizzoni A, Favoni RE. Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines. Br J Pharmacol. 1997 Feb;120(3):537-43. PubMed PMID: 9031761; PubMed Central PMCID: PMC1564490. 10: Frigerio E, Magi N, Benecchi A, Pianezzola E, Strolin Benedetti M. Determination of FCE 26644, a new polysulphonated derivative of distamycin A, in monkey plasma by reversed-phase ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr A. 1996 Apr 5;729(1-2):237-42. PubMed PMID: 9004945. 11: Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N, Grandi M. Antitumor activity of FCE 26644 a new growth-factor complexing molecule. Cancer Chemother Pharmacol. 1995;36(3):217-22. PubMed PMID: 7781141. 12: Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, Mongelli N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol. 1994 Jan 20;47(2):295-302. PubMed PMID: 7508230.